A Phase 1 interventional study of 400 µg Brimonidine Tartrate Implant and 200 µg Brimonidine Tartrate Implant in Vitrectomy, sponsored by Allergan. Completed at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-05.
Sponsored by Allergan (part of AbbVie) · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System in patients 2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy.
Allergan is the lead sponsor of 505 studies on the registry; none are open to participants now.
Of its 93 completed or terminated interventional studies of FDA-regulated products, 91 (98%) have results posted.
First submitted before Allergan became part of AbbVie.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
Drug: 400 µg Brimonidine Tartrate Implant
200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
Drug: 200 µg Brimonidine Tartrate Implant
400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
Also known as: Brimonidine Tartrate PS DDS®
200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
Also known as: Brimonidine Tartrate PS DDS®
Highest Vitreous Humor Level of Brimonidine in the Study Eye
The highest level of brimonidine measured in the vitreous humor of the study eye in any patient is reported for each treatment arm. The vitreous humor is the clear gel that fills the space between the lens and the retina of the eye.
Time frame: 60 Days
Highest Aqueous Humor Level of Brimonidine in the Study Eye
The highest level of brimonidine measured in the aqueous humor of the study eye in any patient is reported for each treatment arm. The aqueous humor is the clear fluid in the chamber of the eye between the cornea and the lens.
Time frame: 60 Days
Percentage of Patient Samples With Plasma Levels of Brimonidine Below the Limit of Quantitation (BLQ)
Percentage of patient samples with plasma levels of brimonidine reported as BLQ (i.e., too low to be determined using standard methods). Plasma is the fluid portion of the blood.
Time frame: 60 Days
| Milestone | 400 µg Brimonidine Tartrate Implant | 200 µg Brimonidine Tartrate Implant |
|---|---|---|
| Started | 12 | 12 |
| Completed | 7 | 9 |
| Not completed | 5 | 3 |
The highest level of brimonidine measured in the vitreous humor of the study eye in any patient is reported for each treatment arm. The vitreous humor is the clear gel that fills the space between the lens and the retina of the eye.
| Nanogram/milliliter (ng/mL) | 400 µg Brimonidine Tartrate Implant | 200 µg Brimonidine Tartrate Implant |
|---|---|---|
| Highest Vitreous Humor Level of Brimonidine in the Study Eye | 137.0 | 34.9 |
The highest level of brimonidine measured in the aqueous humor of the study eye in any patient is reported for each treatment arm. The aqueous humor is the clear fluid in the chamber of the eye between the cornea and the lens.
| Nanogram/milliliter (ng/mL) | 400 µg Brimonidine Tartrate Implant | 200 µg Brimonidine Tartrate Implant |
|---|---|---|
| Highest Aqueous Humor Level of Brimonidine in the Study Eye | 17.5 | 12.5 |
Percentage of patient samples with plasma levels of brimonidine reported as BLQ (i.e., too low to be determined using standard methods). Plasma is the fluid portion of the blood.
| Percentage of Patient Samples | 400 µg Brimonidine Tartrate Implant | 200 µg Brimonidine Tartrate Implant |
|---|---|---|
| Percentage of Patient Samples With Plasma Levels of Brimonidine Below the Limit of Quantitation (BLQ) | 53.3 | 72.6 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 400 µg Brimonidine Tartrate Implant | — | 1/12 (8.3%) | 11/12 (91.7%) |
| 200 µg Brimonidine Tartrate Implant | — | 2/12 (16.7%) | 12/12 (100%) |
| Event | 400 µg Brimonidine Tartrate Implant | 200 µg Brimonidine Tartrate Implant |
|---|---|---|
| Choroidal DetachmentEye disorders | 1/12 | 0/12 |
| Atrial FibrillationCardiac disorders | 1/12 | 0/12 |
| Vitreous HaemorrhageEye disorders | 0/12 | 1/12 |
| Retinal DetachmentEye disorders | 0/12 | 1/12 |
| Event | 400 µg Brimonidine Tartrate Implant | 200 µg Brimonidine Tartrate Implant |
|---|---|---|
| Conjunctival HaemorrhageEye disorders | 7/12 | 6/12 |
| Conjunctival HyperaemiaEye disorders | 5/12 | 7/12 |
| Intraocular Pressure IncreasedInvestigations | 1/12 | 3/12 |
| Conjunctival OedemaEye disorders | 2/12 | 2/12 |
| HypertensionVascular disorders | 2/12 | 0/12 |
| Vitreous HaemorrhageEye disorders | 0/12 | 2/12 |
| Retinal DetachmentEye disorders | 0/12 | 2/12 |
| NasopharyngitisInfections and infestations | 1/12 | 1/12 |
| CataractEye disorders | 1/12 | 1/12 |
| Eye PainEye disorders | 1/12 | 1/12 |
| Age Continuous(Years) | 400 µg Brimonidine Tartrate Implant | 200 µg Brimonidine Tartrate Implant | Total |
|---|---|---|---|
| Mean | 69.7 ± 2.87 | 66.5 ± 9.67 | 68.1 (53 to 78) |
| Sex: Female, Male(Participants) | 400 µg Brimonidine Tartrate Implant | 200 µg Brimonidine Tartrate Implant | Total |
|---|---|---|---|
| Female | 8 | 6 | 14 |
| Male | 4 | 6 | 10 |
The record gives a start of Dec 2010, a primary completion of May 2011 and a completion of Oct 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Brimonidine